SCHEMBL719443

SCHEMBL719443

CC(C)c1ccc(S(=O)(=O)O)c(C(C)C)c1C(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.41
FABP4 P15090 1/20 0.41
FABP5 Q01469 1/20 0.41
SLC9A1 P19634 2/20 0.35
SLC9A2 Q9UBY0 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
LMNA P02545 2/20 0.31
SLC6A2 P23975 2/20 0.31
HTR2B P41595 2/20 0.31
TRPA1 O75762 1/20 0.31
CHRM1 P11229 1/20 0.31
ADRA1A P35348 1/20 0.31
CYP1A2 P05177 2/20 0.31
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
GABRA1 P14867 2/20 0.31
GABRB2 P47870 2/20 0.31
HPGD P15428 2/20 0.31
FAAH O00519 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1005423 0.98 FABP3 (0.40) FABP3FABP4FABP5SLC9A1SLC9A2
Ammonia Solution, Strong SCHEMBL11578768 0.98 FABP3 (0.40) FABP3FABP4FABP5SLC9A1SLC9A2
SCHEMBL2553027 0.82 GABRA1 (0.43) FABP3FABP4FABP5L3MBTL1LMNA
Imidazole SCHEMBL1006649 0.82 ALDH1A1 (0.35) FABP3FABP4FABP5ALDH1A1
Tetrazole SCHEMBL2254943 0.82 FABP3 (0.30) FABP3FABP4FABP5
SCHEMBL971368 0.82 L3MBTL1 (0.32) FABP3FABP4FABP5SLC9A1SLC9A2
Ammonia Solution, Strong SCHEMBL23749140 0.81 GABRA1 (0.42) FABP3FABP4FABP5L3MBTL1LMNA
SCHEMBL216708 0.80 TRPV4 (0.38) SLC9A1SLC9A2L3MBTL1HPGDALDH1A1
SCHEMBL10980384 0.80 L3MBTL1 (0.32) SLC9A1SLC9A2L3MBTL1HPGDALDH1A1
SCHEMBL30010765 0.80 TRPV4 (0.38) SLC9A1SLC9A2L3MBTL1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1163550-B1 HYDROXY-AMINO THERMALLY CURED UNDERCOAT FOR 193 NM LITHOGRAPHY FUJIFILM ELECTRONIC MATERIALS (US) 2007-05-30 EP claimed
US-7026478-B2 Iron catalyzed cross coupling reactions of aromatic compounds STUDIENGESELLSCHAFT KOHLE MBH (DE) 2006-04-11 US claimed
US-20030220498-A1 Iron catalyzed cross coupling reactions of aromatic compounds STUDIENGESELLSCHAFT KOHLE MBH (DE) 2003-11-27 US claimed
US-5473104-A Reacting sulfonated 3-hydroxybutyrolactone with trimethylamine , decyclization NEUROCRINE BIOSCIENCES, INC. (US) 1995-12-05 US claimed
US-5276149-A Antibiotics MERCK & CO., INC. (US) 1994-01-04 US claimed
EP-4346815-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Schrödinger, Inc. (US) 2024-04-10 EP disclosed
EP-4288436-A1 TRICYCLIC COMPOUNDS AND USES THEREOF HUTCHMED Limited (CN) 2023-12-13 EP disclosed
CN-113677293-B Curable composition for dental restoration 可乐丽则武齿科株式会社 2023-10-10 CN disclosed
WO-2022262691-A1 HETEROCYCLIC COMPOUNDS AS SOS1 INHIBITORS BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) 2022-12-22 WO disclosed
WO-2022171018-A1 SUBSTITUTED BENZOPYRIMIDINE OR PYRIDOPYRIMIDINE AMINE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州泽璟生物制药股份有限公司 2022-08-18 WO disclosed
WO-2022083657-A1 SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 苏州泽璟生物制药股份有限公司 2022-04-28 WO disclosed
CN-102844114-B For preparing the metal catalyst composition of furfural derivatives from lignocellulosic biomass raw material and utilizing the preparation method of furfural derivatives of this metal catalyst composition 韩国生产技术研究院 2016-06-08 CN disclosed
WO-1984001779-A1 PROCESS FOR THE PRODUCTION OF OLIGONUCLEOTIDES KOESTER HUBERT (DE) 1984-05-10 WO disclosed
EP-0102995-A1 POLYNUCLEOTIDE SYNTHESIS CELLTECH LIMITED (GB) 1984-03-21 EP disclosed
US-4409209-A POTENTIATION OF ANTIBIOTICS CIBA-GEIGY CORPORATION (US) 1983-10-11 US disclosed
WO-1983003098-A1 POLYNUCLEOTIDE SYNTHESIS EATON, MICHAEL, ANTHONY, WILLIAM 1983-09-15 WO disclosed
US-4323560-A IMMUNOPOTENTIATING ACTION TO INCREASE ANTIBIOTIC EFFECTIVENESS CIBA-GEIGY CORPORATION (US) 1982-04-06 US disclosed
EP-0027258-A1 Phosphoryl muramyl peptides, method for their preparation and their use in medicines CIBA-GEIGY AG (CH) 1981-04-22 EP disclosed
US-4194952-A BY EVAPORATION OF WATER WITH ADDITION OF ANTIFORAM AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1980-03-25 US disclosed
US-4056673-A VIRICIDE, ANTINEOPLASTIC HOFFMANN-LA ROCHE INC. (US) 1977-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220498-A1 Iron catalyzed cross coupling reactions of aromatic compounds ARRB1, RBX1, CYP4X1 FABP3 3840/4885FABP4 3224/4885FABP5 4412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.